CeriBell (NASDAQ:CBLL) Director Sells $573,500.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Josef Parvizi sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $22.94, for a total transaction of $573,500.00. Following the sale, the director owned 747,652 shares in the company, valued at approximately $17,151,136.88. This trade represents a 3.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Josef Parvizi also recently made the following trade(s):

• On Monday, December 15th, Josef Parvizi sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $21.49, for a total value of $537,250.00.
• On Monday, December 8th, Josef Parvizi sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $20.26, for a total value of $506,500.00.

CeriBell Price Performance

CBLL stock opened at $22.69 on Friday. The stock has a market capitalization of $841.80 million, a price-to-earnings ratio of -15.03 and a beta of 1.02. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $26.04. The stock’s fifty day simple moving average is $19.92 and its 200-day simple moving average is $15.33.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The firm had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. Equities research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on CBLL shares. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Monday, December 15th. JPMorgan Chase & Co. dropped their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Raymond James Financial initiated coverage on CeriBell in a report on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 target price on the stock. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, Canaccord Genuity Group raised their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and an average price target of $24.67.

Institutional Investors Weigh In On CeriBell

A number of large investors have recently modified their holdings of CBLL. SG Americas Securities LLC acquired a new position in CeriBell during the 4th quarter worth approximately $145,000. JPMorgan Chase & Co. raised its stake in shares of CeriBell by 8.2% during the third quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock valued at $4,724,000 after purchasing an additional 31,177 shares during the period. Sherbrooke Park Advisers LLC acquired a new position in shares of CeriBell during the third quarter worth $135,000. Millennium Management LLC boosted its stake in shares of CeriBell by 41.8% in the third quarter. Millennium Management LLC now owns 666,448 shares of the company’s stock valued at $7,657,000 after purchasing an additional 196,299 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of CeriBell by 87.1% in the third quarter. Bank of America Corp DE now owns 135,783 shares of the company’s stock valued at $1,560,000 after purchasing an additional 63,215 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.